Patents by Inventor Bum-Tae Kim
Bum-Tae Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12202876Abstract: The present invention relates to a transmembrane domain derived from human LRRC24 protein. More specifically, the present invention relates to a transmembrane domain derived from the human LRRC24 protein (LRRC24P transmembrane domain) or a cell-penetrating peptide, and an intracellular delivery system comprising same. The transmembrane domain derived from the human LRRC24 protein of the present invention can be used to deliver cargo materials such as compounds, biomolecules, and various polymer materials into cells. Since the LRRC24P transmembrane domain of the present invention exhibits higher cell penetration efficiency compared to conventional cell-penetrating peptides and is derived from human proteins, thus avoiding side effects and immune responses caused by peptides derived from foreign proteins, it can be usefully used as an effective intracellular delivery method for compounds, biomolecules, and various polymer materials applied to the human body.Type: GrantFiled: December 16, 2019Date of Patent: January 21, 2025Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Seong Jun Kim, Kyun Do Kim, In Su Hwang, Keunbon Ku, Chonsaeng Kim, Bum Tae Kim, Dae Gyun Ahn, Hae Soo Kim, Young Chan Kwon
-
Publication number: 20240319186Abstract: The present invention relates to a nanowire-based immunofluorescence kit for detecting a SARS coronavirus 2 antibody, and a use thereof, and more specifically, to a zinc oxide nanowire-based immunofluorescence kit for detecting a SARS coronavirus 2 antibody, and a use thereof, the kit comprising a step of growing nanowires on a substrate, introducing a functional group on the grown nanowires, and fixing a SARS coronavirus 2 antigen. The nanowire array of the present invention has enhanced detection sensitivity to enable more accurate diagnosis of whether or not a SARS coronavirus 2 antibody is produced.Type: ApplicationFiled: January 11, 2022Publication date: September 26, 2024Inventors: Hong Gi KIM, Jung KIM, Bum Tae KIM, Jonghwan LEE, Nam Hoon KIM, Sung Kyun LEE
-
Patent number: 11767297Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.Type: GrantFiled: September 7, 2022Date of Patent: September 26, 2023Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITYInventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
-
Publication number: 20230220012Abstract: Provided are a recombinant antigen comprising a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof, a vaccine composition comprising the recombinant antigen, a gene construct comprising a polynucleotide encoding the recombinant antigen, a recombinant vector comprising the gene construct, a method for producing the SARS-CoV-2 recombinant antigen, and a kit for preventing or treating SARS-CoV-2 infection comprising the vaccine composition and users' instruction thereof, wherein the antigen exhibited higher immunogenicity against SARS-CoV-2 the neutralizing antibody was better formed in actual animal experiments, excellent protective immunity was induced, and toxicity did not appear in the toxicity test.Type: ApplicationFiled: May 13, 2021Publication date: July 13, 2023Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Seong Jun KIM, Chonsaeng KIM, Kyun Do KIM, Dae Gyun AHN, Young Chan KWON, Keunbon KU, Hae Soo KIM, Hye Jin SHIN, Gun Young YOON, In Su HWANG, Gi Uk JEONG, Sun Hee LEE, Mi Hwa KIM, Su Min LEE, Bum Tae KIM
-
Publication number: 20230160895Abstract: Provided are a composition for detecting SARS coronavirus 2, a composition for diagnosing SARS coronavirus 2 infection, a method for detecting SARS coronavirus 2, and a SARS coronavirus 2 infection diagnostic kit, wherein a receptor and an antibody that binds to SARS coronavirus 2 spike protein are used in order to detect SARS coronavirus 2 (SARS-CoV-2) or diagnose SARS coronavirus 2 infection (COVID-19).Type: ApplicationFiled: June 18, 2021Publication date: May 25, 2023Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Hong Gi KIM, Jonghwan LEE, Bum Tae KIM
-
Publication number: 20230039679Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.Type: ApplicationFiled: September 7, 2022Publication date: February 9, 2023Inventors: Sung Youn CHANG, Hyuk LEE, Ki Young KIM, Bum Tae KIM, Sung Soo KIM, Seong Hwan KIM, Hwan Jung LIM, Jung Nyoung HEO, Sang Joon SHIN, Sang Youn PARK
-
Patent number: 11485711Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.Type: GrantFiled: January 31, 2019Date of Patent: November 1, 2022Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITYInventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
-
Publication number: 20220306718Abstract: The present invention relates to a transmembrane domain derived from human LRRC24 protein. More specifically, the present invention relates to a transmembrane domain derived from the human LRRC24 protein (LRRC24P transmembrane domain) or a cell-penetrating peptide, and an intracellular delivery system comprising same. The transmembrane domain derived from the human LRRC24 protein of the present invention can be used to deliver cargo materials such as compounds, biomolecules, and various polymer materials into cells. Since the LRRC24P transmembrane domain of the present invention exhibits higher cell penetration efficiency compared to conventional cell-penetrating peptides and is derived from human proteins, thus avoiding side effects and immune responses caused by peptides derived from foreign proteins, it can be usefully used as an effective intracellular delivery method for compounds, biomolecules, and various polymer materials applied to the human body.Type: ApplicationFiled: December 16, 2019Publication date: September 29, 2022Inventors: Seong Jun KIM, Kyun Do KIM, In Su HWANG, Keunbon KU, Chonsaeng KIM, Bum Tae KIM, Dae Gyun AHN, Hae Soo KIM, Young Chan KWON
-
Patent number: 11447469Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.Type: GrantFiled: January 31, 2019Date of Patent: September 20, 2022Assignees: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
-
Publication number: 20210047277Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.Type: ApplicationFiled: January 31, 2019Publication date: February 18, 2021Applicants: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Sung Youn CHANG, Hyuk LEE, Ki Young KIM, Bum Tae KIM, Sung Soo KIM, Seong Hwan KIM, Hwan Jung LIM, Jung Nyoung HEO, Sang Joon SHIN, Sang Youn PARK
-
Publication number: 20210047300Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.Type: ApplicationFiled: January 31, 2019Publication date: February 18, 2021Applicants: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Sung Youn CHANG, Hyuk LEE, Ki Young KIM, Bum Tae KIM, Sung Soo KIM, Seong Hwan KIM, Hwan Jung LIM, Jung Nyoung HEO, Sang Joon SHIN, Sang Youn PARK
-
Patent number: 9018233Abstract: The invention relates to diaminoaryl derivatives substituted by carbamate, salts thereof and a pesticidal composition containing the same, which exhibit superior pest control effects against various insect pests of insect species, in particular against moths such as the diamondback moth or Spodoptera litura.Type: GrantFiled: May 7, 2013Date of Patent: April 28, 2015Assignees: Kyung Nong Corporation, Korea Research Institute of Chemical TechnologyInventors: Sung Youn Chang, Jung Nyoung Heo, Hyuk Lee, Hwan Jung Lim, Bum Tae Kim, Joo Kyung Kim, Jong-Kwan Kim
-
Publication number: 20150094342Abstract: The invention relates to diaminoaryl derivatives substituted by carbamate, salts thereof and a pesticidal composition containing the same, which exhibit superior pest control effects against various insect pests of insect species, in particular against moths such as the diamondback moth or Spodoptera litura.Type: ApplicationFiled: May 7, 2013Publication date: April 2, 2015Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, KYUNG NONG CORPORATIONInventors: Sung Youn Chang, Jung Nyoung Heo, Hyuk Lee, Hwan Jung Lim, Bum Tae Kim, Joo Kyung Kim, Jong-Kwan Kim
-
Patent number: 8716326Abstract: The present invention relates to an amide compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition comprising the same. The inventive amide compound facilitates bone formation and inhibits bone loss, and is therefore useful for preventing and treating bone disorders such as osteoporosis, osteodystrophy, bone fracture, periodontal disease, Paget's disease, bone metastasis, and rheumatoid arthritis.Type: GrantFiled: May 14, 2010Date of Patent: May 6, 2014Assignee: Korea Research Institute of Chemical TechnologyInventors: Jung Nyoung Heo, Bum Tae Kim, Hyuk Lee, Sung Youn Chang, Zang Hee Lee, Seong Hwan Kim, Hyun-Mo Ryoo
-
Patent number: 8227456Abstract: The present invention relates to a use of a specific alpha-arylmethoxyacrylate derivative, or its pharmacologically acceptable salt or solvate for preventing and treating metabolic bone diseases.Type: GrantFiled: October 14, 2009Date of Patent: July 24, 2012Assignees: Korea Research Institute of Chemical Technology, Oscotec Inc.Inventors: Bum Tae Kim, Yong Ki Min, Yeon Soo Lee, Jung Nyoung Heo, Hyuk Lee, No Kyun Park, Jung-Keun Kim, Se-Won Kim, Seon-Yle Ko
-
Publication number: 20120065396Abstract: The present invention relates to an amide compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition comprising the same. The inventive amide compound facilitates bone formation and inhibits bone loss, and is therefore useful for preventing and treating bone disorders such as osteoporosis, osteodystrophy, bone fracture, periodontal disease, Paget's disease, bone metastasis, and rheumatoid arthritis.Type: ApplicationFiled: May 14, 2010Publication date: March 15, 2012Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Jung Nyoung Heo, Bum Tae Kim, Hyuk Lee, Sung Youn Chang, Zang Hee Lee, Seong Hwan Kim, Hyun-Mo Ryoo
-
Patent number: 7879835Abstract: The present invention relates to a use of a specific alpha-arylmethoxyacrylate derivative, or its pharmacologically acceptable salt or solvate for preventing and treating metabolic bone diseases.Type: GrantFiled: June 22, 2005Date of Patent: February 1, 2011Assignees: Korea Research Institute of Chemical Technology, Oscotec Inc.Inventors: Bum Tae Kim, Yong Ki Min, Yeon Soo Lee, Jung Nyoung Heo, Hyuk Lee, No Kyun Park, Jung-Keun Kim, Se-Won Kim, Seon-Yle Ko
-
Publication number: 20100256367Abstract: The present invention relates to a use of a specific alpha-arylmethoxyacrylate derivative, or its pharmacologically acceptable salt or solvate for preventing and treating metabolic bone diseases.Type: ApplicationFiled: October 14, 2009Publication date: October 7, 2010Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, OSCOTEC INC.Inventors: Bum Tae KIM, Yong Ki Min, Yeon Soo Lee, Jung Nyoung Heo, Hyuk Lee, No Kyun Park, Jung-Keun Kim, Se-Won Kim, Seon-Yle Ko
-
Publication number: 20100144712Abstract: A triazole derivative of formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof is superior to the conventional antifungal drugs in antifungal activity against a wide spectrum of pathogenic fungi, and has advantageously low toxicity.Type: ApplicationFiled: June 12, 2008Publication date: June 10, 2010Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, CHEMON INC.Inventors: Bum Tae Kim, Yong Ki Min, Jung Nyoung Heo, Hyuk Lee, Sung Youn Chang, No Kyun Park, Si-Whan Song, Jung-Ja Oh
-
Publication number: 20080280901Abstract: The present invention relates to a use of a specific alpha-arylmethoxyacrylate derivative, or its pharmacologically acceptable salt or solvate for preventing and treating metabolic bone diseases.Type: ApplicationFiled: June 22, 2005Publication date: November 13, 2008Applicants: Korea Research Institute of Chemical Technology, Oscotec Inc.Inventors: Bum Tae Kim, Yong Ki Min, Yeon Soo Lee, Jung Nyoung Heo, Hyuk Lee, No Kyun Park, Jung-Keun Kim, Se-Won Kim, Seon-Yle Ko